 Biotech + AI: Where Big Capital Is Looking in 2026 2026 has become the year when the venture world finally placed its bets. Four of the five largest rounds in history closed in the first quarter. AI companies attracted 80% of all venture dollars — $242 billion. But the most interesting developments are happening at the intersection: biotech startups with an AI core are experiencing an unprecedented boom. Why This Matters The market has stopped believing in "AI for AI's sake." Capital flows where artificial intelligence solves a specific applied problem — diagnostics, drug discovery, personalized medicine. Digital health posted a record Q1 with $4 billion in investments. Large funds no longer ask "why do you need AI." They ask "how fast can you scale with AI." How This Relates to ASI Biont We are building a team of AI agents that analyze market data, find LPR contacts, handle correspondence, and create content — in seconds, not days. For a biotech startup, where speed to market is everything, this is not an advantage but a necessity. Our agents have already shown: automating routine processes reduces the deal cycle by an order of magnitude. In a world where capital concentrates at the top, the one who is faster survives. 1500 tokens to start — for the first 100 users who want to test the AI team on their tasks. No promo codes, no hidden conditions. 2026 Trend: AI is not hype, but infrastructure. And we are building within that infrastructure.